Ask AI

Discordant Guidelines: To Treat or Not to Treat HCV During Pregnancy?

Clinical Thought
Clinical Thought Start Activity

Released: November 20, 2026

See Activity Collection

In recent years, the burden of hepatitis C virus (HCV) infection has shifted toward younger populations, including pregnant people. However, infectious disease and obstetrics guidelines are split on whether pregnant people with HCV should be treated during pregnancy or postpartum. Keep reading to learn when I believe pregnant people should be treated for HCV to optimize their odds for retention in care and prevention of perinatal transmission.

HCV During Pregnancy

Historically, before the adoption of widespread screening measures, hepatitis C virus (HCV) infection was most prevalent among baby boomers, largely due to healthcare-related exposures or via the blood supply. However, in recent years, the opioid epidemic has become a major driver of HCV transmission, shifting the burden of infection toward younger populations, including pregnant women. This shift presents a unique challenge, as HCV can be transmitted perinatally from mother to infant, at a rate of approximately 6 percent. In addition, HCV infection during pregnancy increases the risk of cholestasis of pregnancy, which can be associated with fetal growth restriction, preterm birth, and stillbirth.

Universal HCV Screening in Pregnancy
Every healthcare professional (HCP) involved in the care of pregnant people should prioritize screening for HCV. In 2018, the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) were the first societies to recommend universal hepatitis C screening in pregnancy. Then the CDC started to recommend universal hepatitis C screening in pregnancy in 2020. Finally, the American College of Obstetrics and Gynecology (ACOG) and the Society of Maternal-Fetal Medicine (SMFM), followed suit in 2021.

The current issue is engagement and retention in care. Now that we are universally screening people for hepatitis C in pregnancy, we must ensure that they receive the proper treatment and follow-up once they are diagnosed. Often, that requires referral to a hepatologist. Once the infant is born, we also need to follow up with the baby to determine if perinatal transmission occurred. Both engaging the birth parent and following up with the infant are significant gaps, and every HCP involved in the care of pregnant people has a role here.

Postpartum Starts
To address these gaps, let’s start with linking pregnant people to hepatitis C care. The guidelines are split on this issue. The AASLD/IDSA guidelines say that hepatitis C can be treated in pregnancy on a case-by-case basis through shared clinical decision-making. However, the ACOG and SMFM guidelines say that HCV treatment in pregnancy should not occur outside the context of a clinical trial. This disparity in the guidelines is a real challenge to overcome, because obstetrics HCPs will usually follow the guidelines published by obstetrics societies, and pregnant people generally see obstetrics HCPs more frequently than hepatologists or infectious disease HCPs.

Unfortunately, studies show that fewer than 10% of women are treated for HCV in the postpartum year. In my experience, people who wait to initiate HCV treatment often have multiple pregnancies before finally beginning treatment, with risk for perinatal transmission with each pregnancy. That's a significant lost opportunity.

I think part of the problem is that the postpartum period is often very challenging. Ultimately, it is not a great time to initiate a new healthcare intervention. There are some promising novel approaches, like pairing either the delivery visit or the initial postpartum visit with the initiation of hepatitis C treatment, although these interventions have not been implemented or studied on a large scale.

In my own practice, I see many pregnant women who have hepatitis C. If they decide they want postpartum treatment, we arrange a treatment plan and schedule a virtual visit to initiate treatment in the postpartum period. However, even with a prearranged virtual visit, many patients are still lost to follow-up in the postpartum period.

Treatment During Pregnancy
Ultimately, I think the best way to get pregnant women treated for HCV is to treat during pregnancy. Although there are not currently sufficient data for the guidelines to change from recommending postpartum HCV treatment to recommending treatment during pregnancy, there are several ongoing clinical trials and real-world studies assessing HCV treatment during pregnancy. In particular, my coinvestigators and I have been conducting the STORC study, a phase IV, multicenter study of sofosbuvir/velpatasvir for chronic HCV during pregnancy. The results will come out in the spring of 2027, but preliminary data support sofosbuvir/velpatasvir as a safe and efficacious way of treating HCV in pregnant individuals.

Overall, I believe the field of HCV management has shifted towards understanding that we have to meet people where they are. If they're incarcerated, we meet them there. If they're at the methadone clinic, we meet them there. If they're in the obstetrics clinic, we must meet them there as well. So, I think people are much more open to the idea of initiating HCV treatment in pregnancy. The sooner we can get pregnant people treated, the more we reduce the risk of perinatal transmission and health complications.

To learn more about HCV (and hepatitis B virus) screening and treatment in women’s health, join my colleagues and me at our virtual Women’s Health Update.

Your Thoughts
What evidence would you need to see before feeling confident initiating HCV treatment during pregnancy? If you already would, what evidence influenced that decision? Leave a comment to join the discussion!